{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:29:17Z","timestamp":1782246557362,"version":"3.54.5"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>The purpose of this study was to explore the effect of nicorandil on the incidence of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study randomized 300 patients undergoing percutaneous coronary intervention to receive conventional treatment in the control group (hydration only; n = 150) vs. nicorandil therapy (nicorandil 10 mg three times daily plus hydration; n = 150). The primary endpoint was the incidence of contrast-induced nephropathy, defined as rise in serum creatinine \u226544.2 \u03bcmol\/L or &gt;25% above baseline within 72 hours after exposure to contrast administered during percutaneous coronary intervention. Secondary endpoints included differences in post-percutaneous coronary intervention serum creatinine, blood urea nitrogen, creatinine clearance rate, cystatin-C, and occurrence of major adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Contrast-induced nephropathy incidence was 3.3% (5\/150) in the nicorandil group vs. 10.7% (16\/150) in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). At 48 and 72 hours after contrast administration, cystatin-C levels were significantly lower and creatinine clearance rate were significantly higher with nicroandil therapy compared to conventional treatment (all <jats:italic toggle=\"yes\">P<\/jats:italic> values &lt;0.05). No statistical difference was observed in the incidence of major post-procedure side effect events in hospital and fourteen days of follow-up period between the nicorandil group and control group (3.3% vs. 4.0%, <jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Compared to conventional treatment, oral nicorandil therapy was associated with less contrast-induced nephropathy and improved renal function following contrast administration during percutaneous coronary intervention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000826","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T07:48:30Z","timestamp":1572248910000},"page":"284-288","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of nicorandil on the prevention of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention"],"prefix":"10.1097","volume":"31","author":[{"given":"Xue","family":"Zhang","sequence":"first","affiliation":[{"name":"Graduate School, Tianjin Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naikuan","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tianjin Chest Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230924","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11255-017-1718-4","article-title":"The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.","volume":"50","author":"Fu","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"R2-20230924","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/ajkd.2002.32766","article-title":"Hospital-acquired renal insufficiency.","volume":"39","author":"Nash","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R3-20230924","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s11255-016-1348-2","article-title":"Does N-terminal pro-brain natriuretic peptide add prognostic value to the mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention?","volume":"48","author":"Liu","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"R4-20230924","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jcin.2016.01.029","article-title":"An effective and safe hydration method for the prevention of contrast-induced nephropathy.","volume":"9","author":"Qian","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R5-20230924","first-page":"362725","article-title":"Acute kidney injury by radiographic contrast media: pathogenesis and prevention.","volume":"2014","author":"Andreucci","year":"2014","journal-title":"Biomed Res Int"},{"key":"R6-20230924","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.kjms.2017.03.003","article-title":"Effects of nicorandil on renal function and histopathology in rats with partial unilateral ureteral obstruction.","volume":"33","author":"Ozturk","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"R7-20230924","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.vph.2016.12.004","article-title":"Vascular calcification abrogates the nicorandil mediated cardio-protection in ischemia reperfusion injury of rat heart.","volume":"89","author":"Ravindran","year":"2017","journal-title":"Vascul Pharmacol"},{"key":"R8-20230924","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijsu.2016.09.007","article-title":"Risk factors for contrast-induced nephropathy and their association with mortality in patients with blunt splenic injuries.","volume":"35","author":"Hsieh","year":"2016","journal-title":"Int J Surg"},{"key":"R9-20230924","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s11255-018-1814-0","article-title":"Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials.","volume":"50","author":"Ma","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"R10-20230924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/dna.2016.3463","article-title":"Contrast media-induced renal inflammation is mediated through HMGB1 and its receptors in human tubular cells.","volume":"36","author":"Guan","year":"2017","journal-title":"DNA Cell Biol"},{"key":"R11-20230924","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/jcm8020147","article-title":"Does resveratrol play a role in decreasing the inflammation associated with contrast induced nephropathy in rat model.","volume":"8","author":"Chen","year":"2019","journal-title":"J Clin Med"},{"key":"R12-20230924","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s13244-013-0291-3","article-title":"Contrast-induced nephropathy: pharmacology, pathophysiology and prevention.","volume":"4","author":"Geenen","year":"2013","journal-title":"Insights Imaging"},{"key":"R13-20230924","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-8794-2-2","article-title":"Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.","volume":"2","author":"Kell","year":"2009","journal-title":"BMC Med Genomics"},{"key":"R14-20230924","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.amjcard.2010.10.001","article-title":"The editor\u2019s roundtable: contrast agents and risk for contrast-induced nephropathy.","volume":"107","author":"Friedewald","year":"2011","journal-title":"Am J Cardiol"},{"key":"R15-20230924","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21307\/ane-2017-036","article-title":"Nicorandil attenuates neuronal mitochondrial dysfunction and oxidative stress associated with murine model of vascular calcification.","volume":"77","author":"Ravindran","year":"2017","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"R16-20230924","doi-asserted-by":"crossref","first-page":"744","DOI":"10.21037\/jtd.2019.02.23","article-title":"Effect of sequential nicorandil on myocardial microcirculation and short-term prognosis in acute myocardial infarction patients undergoing coronary intervention.","volume":"11","author":"Pi","year":"2019","journal-title":"J Thorac Dis"},{"key":"R17-20230924","doi-asserted-by":"crossref","first-page":"e14165","DOI":"10.1097\/MD.0000000000014165","article-title":"Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: a meta-analysis of randomized controlled trials.","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine"},{"key":"R18-20230924","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0003319716675720","article-title":"Effect of long-term administration of nicorandil on endothelial function of the radial artery in patients with angina undergoing transradial percutaneous coronary intervention.","volume":"68","author":"Fan","year":"2017","journal-title":"Angiology"},{"key":"R19-20230924","first-page":"591","article-title":"Nicorandil pretreatment inhibits myocardial apoptosis and improves cardiac function after coronary microembolization in rats.","volume":"15","author":"He","year":"2018","journal-title":"J Geriatr Cardiol"},{"key":"R20-20230924","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1046\/j.1523-1755.1998.06758.x","article-title":"The K(ATP) channel opener nicorandil: effect on renal hemodynamics in spontaneously hypertensive and wistar kyoto rats.","volume":"67","author":"Kawata","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"R21-20230924","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/MNH.0b013e32834d085a","article-title":"Role of medullary blood flow in the pathogenesis of renal ischemia-reperfusion injury.","volume":"21","author":"Regner","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R22-20230924","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000355060","article-title":"Nicorandil protects against ischaemia-reperfusion injury in newborn rat kidney.","volume":"92","author":"Zhang","year":"2013","journal-title":"Pharmacology"},{"key":"R23-20230924","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1476-5381.2011.01231.x","article-title":"Nicorandil ameliorates ischaemia-reperfusion injury in the rat kidney.","volume":"163","author":"Shimizu","year":"2011","journal-title":"Br J Pharmacol"},{"key":"R24-20230924","doi-asserted-by":"crossref","first-page":"F1313","DOI":"10.1152\/ajprenal.00521.2014","article-title":"Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease.","volume":"307","author":"Shiraishi","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"R25-20230924","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10157-014-0998-6","article-title":"Nicorandil suppresses urinary protein excretion and activates enos in Dahl salt-sensitive hypertensive rats.","volume":"19","author":"Tashiro","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"R26-20230924","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2015.05.078","article-title":"Continuous intravenous infusion of nicorandil for 4 hours before and 24 hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function.","volume":"195","author":"Nawa","year":"2015","journal-title":"Int J Cardiol"},{"key":"R27-20230924","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s00380-016-0809-y","article-title":"Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.","volume":"31","author":"Fan","year":"2016","journal-title":"Heart Vessels"},{"key":"R28-20230924","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3349\/ymj.2013.54.4.957","article-title":"Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE study).","volume":"54","author":"Ko","year":"2013","journal-title":"Yonsei Med J"},{"key":"R29-20230924","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/0003319717732237","article-title":"Effect of nicorandil administration on preventing contrast-induced nephropathy: a meta-analysis.","volume":"69","author":"Zhan","year":"2018","journal-title":"Angiology"},{"key":"R30-20230924","doi-asserted-by":"crossref","first-page":"e12316","DOI":"10.1111\/1755-5922.12316","article-title":"Nicorandil for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials.","volume":"36","author":"Ma","year":"2018","journal-title":"Cardiovasc Ther"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:17:15Z","timestamp":1695539835000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000826","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}